Table 1.
Descriptive statistical indices of sociodemographic and MS-related information.
| Variables | |
|---|---|
| M (SD) | |
| Age (years) | 50.3 (9.6) |
| BMI (kg/m2) | 28.6 (5.4) |
| n (%) | |
| Gender (female/male) | 11/5 (68.8/31.2) |
| Median (range) | |
| EDSS | 5.5 (3–7) |
| Medications | |
| n (%) | |
| No disease-modifying treatments such as tizanidine (and natalizumab) | 8 (50%) |
| Disease-modifying treatments such as interferon beta, glatiramer acetate, dimethyl fumarate, teriflunomide fingolimod, (natalizumab), rituximab, ocrelizumab, and mitoxantrone | 8 (50%) |
| Psychopharmaceuticals, including pain killers and phytopharmaceuticals | |
| No psychopharmaceuticals | 10 (62.5) |
| Phytopharmaceuticals | 3 (18.8) |
| Pregabalin (Lyrica®) | 1 (6.3) |
| Lamotrigine (Lamictal®) | 2 (12.5) |
| OTC pain killers | 6 (37.5) |
Notes: BMI = Body Mass Index; EDSS = Expanded Disability Status Scale; OTC = over the counter.